Phase I and Pharmacokinetic Study of the Cytotoxic Ether Lipid Ilmofosine Administered by Weekly Two-Hour Infusion in Patients with Advanced Solid Tumors

Clinical Cancer Research

Volumn 10, Issue 4, 2004, Pages 1282-1288

  Giantonio, Bruce J ^a,c,d   Derry, Christine ^b   McAleer, Cecilia ^a   McPhillips, Joseph J ^b   O'Dwyer, Peter J ^a,c  

^a FOX CHASE CANCER CENTER   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ILMOFOSINE; ILMOFOSINE SULFOXIDE; LYSOPHOSPHATIDYLCHOLINE; MILTEFOSINE; PERIFOSINE; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOTOXICITY; DIARRHEA; DOSE LIMITING TOXICITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LD 50; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SCORING SYSTEM; SOLID TUMOR; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KINETICS; LIPIDS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PHOSPHOLIPID ETHERS; TIME FACTORS;

EID: 1642398984     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0837-02     Document Type: Article

References (36)

1. Lohmeyer, M., and Workman, P. Growth arrest versus direct cytotoxicity and the importance of molecular structure for the in vitro anti-tumor activity of ether lipids. Br. J. Cancer, 72: 277-286, 1995.
2. Ruiter, G. A., Verheij, M., Zerp, S. F., and van Blitterswijk, W. J. Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. Int. J. Rad. Oncol. Biol. Phys., 49: 415-419, 2001.
3. Andreesen, R., Modollel, M., Weltzien, H. U., Eibl, H., Common, H., Lohr, W., and Munder, P. G. Selective destruction of human leukemic cells by alkyl-lysophospholipids. Cancer Res., 38: 3894-3899, 1978.
4. Berdel, W. E., Fromm, M., Fink, U., Pahlke, W., Bicker, U., Reichert, A., and Rastetter, J. Cytotoxicity of thioether-lysophospholipids in leukemias and tumors of human origin. Cancer Res., 43: 5538-5543, 1983.
5. Neumann, H. A., Herrmann, D. B., and Boerner, D. Inhibition of human tumor colony formation by the new alkyl lysophospholipid ilmofosine. J. Natl. Cancer Inst. (Bethesda), 78: 1087-1093, 1987.
6. Hermann, D. B., Opitz, H. G., and Munder, P. G. Antitumor activity of ilmofosine (BM 41.440) in the 3Lewis-lung carcinoma model. Lipids, 26: 1431-1436, 1991.
7. Girgert, R., Schweizer, P., Bock, I., Narr, R., and Bruchelt, G. Cytotoxicity of ether phospholipid BM 41.440 on neuroblastoma cells. J. Cancer Res. Clin. Oncol., 121: 262-266, 1995.
8. Skala, J. P., Rogers, P. C., Chan, K. W., Khangura, S. S., and Rodriguez, W. C. In vitro effects of ilmofosine on acute lymphoblastic leukemia cells and on normal hemopoietic cells. Prog. Clin. Biol. Res., 377: 63-69, 1992.
9. Hanauske, A. R., Degen, D., Marshall, M. H., Hilsenbeck, S. G., McPhillips, J. J., and Von Hoff, D. D. Preclinical activity of ilmofosine against human tumor colony forming units in vitro. Anticancer Drugs, 3: 43-46, 1992.
10. Herrmann, D. B., Pahlke, W., Opitz, H. G., and Bicker, U. In vivo antitumor activity of ilmofosine. Cancer Treat. Rev., 17: 247-252, 1990.
11. Rodriguez, G., Havlin, K., Burris, H., Wall, J., Schaffer, D., Smith, L., Kalter, S., Brown, T., Cagnola, J., Weiss, G., Kneuper Hall, R., and Von Hoff, D. Phase I clinical trial of ilmofosine, a novel antitumor agent. Proc. Amer. Soc. Clin. Oncol., 10: 114, 1991.
12. WHO. WHO Handbook for Reporting Results of Cancer Treatment. In: WHO Offset Publication. Geneva: WHO, 1979.
13. Noseda, A., Godwin, P. L., and Modest, E. J. Effect of antineoplastic ether lipids on model and biologic membranes. Biochim. Biophys. Acta, 945: 92-100, 1988.
14. Shoji, M., Raynor, R. L., Berdel, W. E., Vogler, W. R., and Kuo, J. F. Effects of thioether phospholipid BM 41.440 on protein kinase C and phorbol esther-induced differentiation of human leukemia HL60 and KG-1 cells. Cancer Res., 48: 6669-6673, 1988.
15. Oishi, K., Zheng, B., White, J. F., Vogler, W. R., and Kuo, J. F. Inhibition of NA K-ATPase and sodium pump by anticancer ether lipids and protein kinase C inhibitors ET-18-OCH3 and BM 41.440. Biochem. Biophys. Res. Commun., 157: 1000-1006, 1988.
16. 2 phase and suppresses CDC2 kinase activation through a mechanism different from that of DNA damaging agents. Biochem. Biophys. Res. Commun., 199: 937-943, 1994.
17. Workman, P. The cell membrane and new cell signals: new targets for novel anticancer drugs. Ann. Oncol., 1: 100-111, 1990.
18. Wagner, B. A., Buettner, G. R., and Burns, C. P. Membrane peroxidative damage enhancement by the ether lipid class of antineoplastic agents. Cancer Res., 52: 6045-6051, 1992.
19. Diomede, L., Colotta, F., Piovani, B., Modest, E. J., and Salmona, M. Induction of apoptosis in human leukemic cells by ether lipid 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine. A possible basis for its selective action. Int. J. Cancer, 53: 124-130, 1993.
20. Herrmann, D. B., Bicker, U., and Pahlke, W. BM 41.440: a new antineoplastic, antimetastatic, and immune-stimulating drug. Cancer Detect. Prev. Suppl., 1: 361-371, 1987.
21. Pignol, B., Chaumeron, S., Coulomb, H., Maisonnet, T., Vandamme, B., Brouquet, C., Mencia-Huerta, J. M., and Braquet, P. Immunomodulatory activity of two new aza alkyl phospholipid antineoplastic drugs. Anticancer Drugs, 3: 599-608, 1992.
22. Koeller, J., Rodriguez, G., Smith, L., Eckardt, J., Shaffer, D., Weiss, G., Higashi, L., McPhillips, J., and Von Hoff, D. Phase I study of ilmofosine given as a 120 hour continuous infusion in patients with solid tumors. Proc. Am. Soc. Clin. Oncol., 12: 421a, 1993.
23. Von Mehren, M., Giantonio, B. J., McAleer, C., Schilder, R., McPhillips, J., and O'Dwyer, P. J. Phase I trial of ilmofosine as a 24 hour infusion weekly. Investig. New Drugs, 13: 205-210, 1995.
24. Woolley, P. V., Schultz, C. J., Rodriguez, G. I., Gams, R. A., Rowe, Jr., K. W., Dadey, M. L., Von Hoff, D. D., and McPhillips, J. J. A Phase II trial of ilmofosine an non-small cell bronchogenic carcinoma. Investig. New Drugs, 14: 219-222, 1996.
25. Winkelman, M., Ebeling, K., Strohmeyer, G., Hottenrott, G., Mechl, Z., Berges, W., Scholten, T., Westerhausen, M., Schlimok, G., and Sterz, R. Treatment results of the thioether lipid ilmofosine in patients with malignant tumors. J. Cancer Res. Clin. Oncol., 118: 405-407, 1992.
26. Ford, H., Watkins, S., Reblock, K., and Rowe, M. The role of inflammatory cytokines and nitric oxide in the pathogenesis of necrotizing enterocolitis. J. Pediatr. Surg., 32: 275-282, 1997.
27. Targan, S. R., Hanauer, S. B., van Deventer, S. J., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., and Rutgeerts, P. J. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med., 337: 1029-1035, 1997.
28. Pauig, S. B., and Daniel, L. W. Protein kinase C inhibition by et-18-och3 and related analogues. Adv. Exp. Med. Biol., 416: 173-180, 1996.
29. Stekar, J., Hilgard, P., and Klenner, T. Opposite effect of miltefosine on the antineoplastic activity and hemotological toxicity of cyclophosphamide. Eur. J. Cancer, 31A: 372-374, 1995.
30. Berkovic, D., Grundel, O., Berkovic, K., Wildfang, I., Hess, C. F., and Schmoll, H. J. Synergistic cytotoxic effects of ether phospholipid analogues and ionizing radiation in human carcinoma cells. Radiother. Oncol., 43: 293-301, 1997.
31. Ruiter, G. A., Zerp, S. F., Bartelink, H., van Blitterswijk, W. J., and Verheij, M. Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res., 59: 2457-2463, 1999.
32. Dummer, R., Roger, J., Vogt, T., Becker, J., Hefner, H., Sindermann, H., and Burg, G. Topical applications hexadecylphosphocholine in patients with cutaneous lymphomas. Prog. Exp. Tumor Res., 34: 160-169, 1992.
33. Clive, S., Gardiner, J., and Leonard, R. C. Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. Cancer Chemother. Pharmacol., 44: S29-S30, 1999.
34. Terwogt, J. M., Mandjes, I. A., Sindermann, H., Beijnen, J. H., and ten Bokkel Hiunink, W. W. Phase II trial of topically applied miltefosine solution in patients with metastasized breast cancer. Br. J. Cancer, 79: 1158-1161, 1999.
35. Maly, K., Uberall, F., Schubert, C., Kindler, E., Stekar, J., Brachwitz, H., and Grunicke, H. H. Interference of new alkylphospholipid analogues with mitogenic signal transduction. Anticancer Drug Des., 10: 411-425, 1995.
36. De Klerk, G., Rosing, H., and Swart, M., Traiser, M., Dubbelman, R., Schellens, J. H. M., Beijnen, J. H., and Ten Bokkel Huinink, W. W. Phase I study of perifosine (D21266), a new alkylphosphocholine analogue. Proc. Am. Soc. Clin. Oncol., 18: 202a, 1999.